RXRX - Company ID 0001601830
RECURSION PHARMACEUTICALS, INC. trades as RXRX and has a market capitalization of $2.02 B, making it the #2130 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $74.68M, up 26.9% from the prior year and net income of -$644.76M. This page tracks RECURSION PHARMACEUTICALS, INC. through 908 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 6 fiscal years RECURSION PHARMACEUTICALS, INC.'s revenue grew from $2.32M to $74.68M, a compound annual growth rate of 78.4%. Net profit margin expanded from -2668.3% to -863.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-22 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| SCHEDULE 13G | - | 2026-05-12 |
| Insider trade | 4 | 2026-05-08 |
| Insider sale notice | 144 | 2026-05-07 |
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 | Recursion Pharmaceuticals, Inc.
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Recursion Pharmaceuticals, Inc.
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | Recursion Pharmaceuticals, Inc.
The largest companies sharing RECURSION PHARMACEUTICALS, INC.'s SEC industry classification (biological products, (no diagnostic substances)).
RECURSION PHARMACEUTICALS, INC. (RXRX) has a market capitalization of $2.02 B as of 2026-07-09, ranking #2130 among US-listed companies.
RECURSION PHARMACEUTICALS, INC. reported revenue of $74.68M for fiscal year 2025, an increase of 26.9% year over year.
In its latest fiscal year RECURSION PHARMACEUTICALS, INC. reported a net loss of $644.76M.